Press release
A Deep Dive into Non-Small Cell Lung Cancer (NSCLC) Market 2025: Key Drivers, Growth Factors, and Projections 2025-2034
Non Small Cell Lung Cancer NSCLC Market Size
The non-small cell lung cancer (NSCLC) market is anticipated to grow due to the escalating consumption of tobacco. Tobacco usage involves smoking, chewing or snuffing tobacco products which infiltrates the body with nicotine and other chemicals. The carcinogens found in tobacco smoke can wreak havoc on the DNA in lung cells and trigger mutations leading to the out-of-control proliferation of cancerous cells, such as in non-small-cell lung cancer (NSCLC). Illustratively, the 2024 National Youth Tobacco Survey, released by the US Food and Drug Administration in October 2024, showed that 1.1% of all students (around 2.25 million) currently used tobacco products. The statistics further revealed that 10.1% of high school students (approximately 1.58 million) and 5.4% of middle school students (around 640,000) were tobacco users. Moreover, 2.8% of students (nearly 760,000) were known to currently use combustible tobacco products, while 3.0% (around 840,000) were registered as users of several tobacco products. Hence, the burgeoning tobacco consumption is steering the growth of the non-small cell lung cancer (NSCLC) market. The surge in air pollution is also foreseen to steer the growth of the non-small cell lung cancer (NSCLC) market. Air pollution, comprising harmful substances or particulates in the air, poses a significant threat to human health. It can elevate the risk of non-small cell lung cancer by inducing inflammation, causing harm to DNA and producing mutations in lung cells - all factors that can eventually lead to the formation of cancerous tumors. The World Health Organization, in June 2023, stated that air and domestic air pollution contributed to 7 million premature deaths per year. It was also found that nearly 2.4 billion people are confronted with perilous household air pollution levels due to the usage of kerosene, biomass and coal for cooking over open fires. Additionally, the World Bank in September 2022 reported that the health damage brought on by air pollution would equate to $8.1 trillion a year or 6.1% of worldwide GDP. Thus, the rise in air pollution is seen to boost the non-small cell lung cancer (NSCLC) market's growth.
Get Your Non-Small Cell Lung Cancer (NSCLC) Market Report Here:
https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report
What is the projected compound annual growth rate (CAGR) of the non-small cell lung cancer (nsclc) market from 2025 to 2034, and what factors influence it?
The market for non-small cell lung cancer (NSCLC) has experienced significant expansion in the recent past. The market, which is projected to escalate from $20.1 billion in 2024 to $22.35 billion in 2025, boasts a compound annual growth rate (CAGR) of 11.1%. The historic period of growth witnessed can be linked to advancements in immunotherapy, genomic profiling, and precision medicine, along with broadening clinical trials and initiatives focusing on stopping smoking.
The market size for non-small cell lung cancer (NSCLC) is projected to experience remarkable growth in the upcoming years and is estimated to reach $33.29 billion by 2029, expanding at a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this projected growth in the forecast period include the evolution of combination treatments, the application of artificial intelligence (AI), the broadening of personalized vaccines, international cooperative efforts in research, and patient-focused care. Significant trends anticipated in the forecast period comprise the incorporation of telemedicine in oncology, the use of liquid biopsy techniques, developments in diagnostic technologies, the implementation of less invasive surgical procedures, and immune checkpoint inhibitors.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp
How are the latest trends influencing the growth of the non-small cell lung cancer (nsclc) market?
Leading firms in the non-small cell lung cancer (NSCLC) sector are devising numerous treatment alternatives like monotherapy treatments to maintain their competitive advantage. Monotherapy treatment refers to the application of a single medication or therapy for treating a disease or condition, relying on a singular method rather than incorporating multiple interventions. For instance, in June 2022, Novartis AG, a pharmaceutical corporation from Switzerland, acquired the approval from the European Commission (EC), a regulatory organization in Belgium, for the use of Tabrecta (capmatinib) to treat adult patients with advanced non-small cell lung cancer exhibiting METex14 skipping. This opens a new therapeutic opportunity for patients in Europe who were previously treated and hold advanced non-small cell lung cancer (NSCLC) with mutations leading to MET exon 14 (METex14) skipping. Currently, it's the most preferred targeted therapy for advanced NSCLC, which carries METex14 skipping mutations.
What are the major segments of the non-small cell lung cancer (nsclc) market and their role in driving growth?
The non-small cell lung cancer (NSCLC) market covered in this report is segmented -
1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232
Which regions are key players in the growth of the non-small cell lung cancer (nsclc) market?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Who are the key firms paving the way for growth in the non-small cell lung cancer (nsclc) market?
Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp
What Is Covered In The Non-Small Cell Lung Cancer (NSCLC) Global Market Report?
•Market Size Forecast: Examine the non-small cell lung cancer (nsclc) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the non-small cell lung cancer (nsclc) market for a structured understanding.
•Key Players Overview: Analyze major players in the non-small cell lung cancer (nsclc) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the non-small cell lung cancer (nsclc) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the non-small cell lung cancer (nsclc) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the non-small cell lung cancer (nsclc) market.
•Industry Challenges: Identify potential risks and obstacles affecting the non-small cell lung cancer (nsclc) market.
•Competitive Landscape: Review strategic developments in the non-small cell lung cancer (nsclc) market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release A Deep Dive into Non-Small Cell Lung Cancer (NSCLC) Market 2025: Key Drivers, Growth Factors, and Projections 2025-2034 here
News-ID: 3914013 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for NSCLC
NSCLC Treatment Market Size, Drugs, Emerging Therapies and Companies 2032 | Delv …
DelveInsight's "NSCLC Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the NSCLC, historical and forecasted epidemiology as well as the NSCLC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Explore the intricate details of the NSCLC Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive NSCLC Market Forecast. Click here to stay ahead in healthcare…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer.
Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how…
